EX-10.14 4 d372009dex1014.htm EX-10.14 EX-10.14

Exhibit 10.14

[*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.


Research Subaward Agreement



Pass-through Entity (PTE)






PTE:  Yale University  

Subrecipient:  Miragen Therapeutics, Inc.


Address:   Office of Sponsored Projects

                 25 Science Park – 3rd Floor

                 150 Munson Street

                 P.O. Box 208327

  Address:  6200 Lookout Road

City, State, Zip+4 (Country): New Haven, CT 06520-8327



City, State, Zip+4 (Country): Boulder, CO 80301


PTE Principal Investigator (PI): [*], MD


  Subrecipient Principal Investigator (PI):    Rusty Montgomery, MD

PTE Federal Award No: 4UH2HL123886-03


  FAIN: UH2HL123886   Federal Awarding Agency:  National Heart, Lung, and Blood Institute

   Project Title:  Mir-29 mimicry as a therapy for pulmonary fibrosis


Subaward Period of Performance:

Start Date:  8/19/2016      End Date:  6/30/2017


  Amount Funded This Action:    [*]  

Amendment No:



Subaward No:

M15A12064 (A10747)      

Effective Date of Amendment:




FFATA Reporting:



Amendment(s) to Original Terms and Conditions

This Amendment revises the above-referenced Research Subaward Agreement as follows:



           Subaward Period of Performance is extended through June 30, 2017.


           Budget Period is August 19, 2016 to June 30, 2017.


           Authorized Funding for Budget Period is [*].


           Pre-award is authorized for July 1, 2016 to August 18, 2016.


All other terms and conditions of this Subaward Agreement remain in full force and effect.
By an Authorized Official of Pass-through Entity:        By an Authorized Official of Subrecipient:





       /s/ Jason A. Leverone




Name: [*]






 Name:   Jason A. Leverone





Title: Award Manager


           Title:     CFO